

### Action Summary – 18 August 2020

Analyst Theodore R. O'Neill – Company reaches major inflection point – raising target to \$43 from \$36

- Revenue grew 15.5x sequentially in a single quarter.** It took Tesla (TSLA-NR) seven quarters (Sept 2012-June 2014) to grow revenue 15x. And like TSLA, at that time, there was deep skepticism about its future. Investors are right to question the future of a company that has this kind of growth, but we believe CODX has built a durable, sustainable business, that unlike TSLA, generated growth and profits simultaneously.
- Like TSLA, CODX is a technology platform.** CODX's proprietary platform and IP allow it to rapidly engineer any number of molecular diagnostic tests that are faster, more specific and with fewer false readings than competitors. Because these tests can be used in any PCR equipped lab (the vast majority) and do not require specialized equipment, the uptake can be rapid and we are seeing that in its growth.
- Not a one hit wonder.** CODX's rise from relative obscurity to a respected molecular diagnostic test provider has given it the wherewithal (both financial and regulatory) to execute on its planned development of multiple new products – and in recognition of this we are projecting growth to continue
- CODX reported 2Q20 results that on the face of it appeared to miss expectations, but it was the estimates that were wrong.** Analysts confronted with companies that are likely to grow 15x in a single quarter are notoriously difficult to model because it is so rare. The company reported EPS of \$0.43 on \$24MM of revenue against consensus EPS and revenue of \$0.59 and \$26.5MM, respectively.
- We have raised our 2020 and 2021 estimates,** 2020 EPS goes to \$1.54 from \$1.42. 2021 EPS goes to \$2.81 from \$1.20. 2021 revenue goes to \$185MM from \$89MM.
- Following the increase in earnings estimates we are reiterating our Buy rating and raising our price target to \$43 from \$36

8/17 Closing price: \$15.64	Market cap: \$437 million	Multiple of book: 13	EV/2021 Sales: 4.1
Shares outstanding: 28 million	Insider ownership: 11%	Avg. 30-day trading volume: 3.5 million	Dividend/Yield: NA/NA

GAAP estimates (EPS in dollars – Revenue in \$000)				Cash balance (in millions)	
Period	EPS	Revenue	Op Margin	• 2018A	• \$1.0
1Q19A	(\$0.09)	\$0.003	NMF	• 2019A	• \$0.9
2Q19A	(\$0.08)	\$0.062	NMF	• 2020E	• \$42.1
3Q19A	(\$0.10)	\$0.041	NMF	• 2021E	• \$115.9
4Q19A	(\$0.10)	\$0.11	NMF		
FY19A	<u>(\$0.37)</u>	<u>\$0.22</u>	<u>NMF</u>		
1Q20A	(\$0.05)	\$1.55	NMF		
2Q20A	\$0.43	\$24.04	51%		
3Q20E	\$0.49	\$30.00	48%		
4Q20E	<u>\$0.56</u>	<u>\$35.00</u>	<u>47%</u>		
FY20E	<u>\$1.54</u>	<u>\$90.59</u>	<u>47%</u>		
1Q21E	\$0.60	\$40.00	44%		
2Q21E	\$0.69	\$45.00	45%		
3Q21E	\$0.77	\$50.00	46%		
4Q21E	<u>\$0.76</u>	<u>\$50.00</u>	<u>45%</u>		
FY21E	<u>\$2.81</u>	<u>\$185.00</u>	<u>45%</u>		
Debt (in millions)					
				• 2018A	• \$0.0
				• 2019E	• \$0.0
				• 2020E	• \$0.0
				• 2021E	• \$0.0
Adjusted EBITDA					
				• 2018A	• (\$6.2)
				• 2019E	• (\$6.1)
				• 2020E	• \$42.7
				• 2021E	• \$83.4

Note: Numbers may not add due to rounding. See our full model in the back of this report.

### Risks/Valuation

- Risks include: Regulatory approval, managing rapid growth
- Our \$43.00 target is derived using a discounted future earnings model

**Company description:** Co-Diagnostics, Inc. is developing robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications.

Figure 1 – Co-Diagnostics, Inc. – 1-Year Trading snapshot



Source: Refinitiv Eikon

## VALUATION METHODOLOGY

We believe CODX is undervalued and we support that belief with two valuation techniques, below. For the purposes of determining our price target we use a discounted future earnings model. The following valuation techniques are being used:

- The discounted value of all future earnings was used for our price target (see Figure 2)
- Valuation relative to peers (see Figure 4)

## Discounted Future Earnings – Basis for Price Target

Our 12-month price target of \$43.00 is based on a discounted earnings model (see Figure 2). This is \$7 above our previous price target and the change is due to our model showing more earnings this year and all out years as the company executes on a long-term strategy to offer a portfolio of diagnostic tests partially offset by raising the discount rate to 8.5% from 7%. Had we not increased the discount rate our price target would have jumped to \$54. For comparison, see Figure 3, the previous price target. Notice, in the previous future earnings stream, we assumed two down years because we thought it might take that long to develop and market new tests. That isn't our view now.

Our valuation model is shown in Figure 2 below. The model sums up all earnings per share, discounted at 8.5% to arrive at a per share value. Near-term EPS shows slow growth, because, again if we had more growth than shown, the price target would just balloon. Note, this model understates future acquisitions, products or markets, probably understates the tax benefits, but offsetting that, the earnings never have a down year.

The implied share price in Figure 2 is \$43.32 which we round down to \$43.00.

Figure 2 – Co-Diagnostics, Inc. – Discounted Future Earnings

	<b>Discounted future earnings</b>	<b>\$43.32</b>
Year	EPS	Discounted EPS
2020	1.54	1.54
2021	2.81	2.59
2022	2.85	2.42
2023	2.90	2.27
2024	2.95	2.13
<b>Terminal Value:</b>		<b>23.57</b>

Source: Litchfield Hills Research LLC

Figure 3 – Co-Diagnostics, Inc. – Previous Discounted Future Earnings

	<b>Discounted future earnings</b>	<b>\$35.54</b>
Year	EPS	Discounted EPS
2020	1.34	1.34
2021	1.20	1.12
2022	1.05	0.92
2023	1.10	0.90
2024	1.20	0.92
<b>Terminal Value:</b>		<b>24.83</b>

Source: Litchfield Hills Research LLC

### Valuation Relative to Peers

If we compare CODX to a simple average of its peers (Figure 4), the shares sell at a discount to 2020-2021 PE and 2020-2021 Sales Multiple and other multiples from 29%-69%. For full details, see our comparable page figure 6.

Figure 4 – Co-Diagnostics, Inc. – Summary Discount to Peers

	2020 PE	2021 PE	2020 Sales Multiple	2021 Sales Multiple
Peers	28.78	25.32	11.45	8.00
CODX	8.97	7.85	4.95	4.03
<b>Discount to Peers</b>	<b>69%</b>	<b>69%</b>	<b>57%</b>	<b>50%</b>

Source: Litchfield Hills Research LLC and Refinitiv Eikon

## Guidance and Financial Forecasts

The company does not provide guidance although it did provide a mid-3Q20 update that it has had sales of \$50MM YTD. Our forecast assumes 2020 test kit growth continues well beyond COVID-19 sales and extends into ABC kits for multiplexing Flu-A, Flu-B and COVID. The company is able to generate a lot of sales without having to hire a lot of people because the company was designed to be highly productive. We believe the company has plenty of cash (\$18.6MM) and is cash flow positive this year.

## Quarterly Results

CODX reported 2Q20 results that on the face of it appeared to miss expectations, but it was the estimates that were wrong. Analysts confronted with companies that are likely to grow 15x in a single quarter are notoriously difficult to model because it is so rare. 2Q20 EPS estimates ranged from our low of \$0.46 to \$0.69. The company reported EPS of \$0.43 on \$24MM of revenue against consensus EPS and revenue of \$0.59 and \$26.5MM, respectively. Relative to our estimates, the company reported a largely in-line quarter. We were looking for \$25MM of revenue and the company reported \$24.04MM. We were looking for EPS of \$0.46 versus the \$0.43 it reported but had we got the share count right, our estimate would have been \$0.43 (the reported and our net income estimates are nearly identical at \$12.6MM) with slightly lower revenue and higher expenses offset by better margins and gain on its Indian JV. See Figure 5.

Figure 5 – Co-Diagnostics, Inc. – Quarterly Variance Analysis (\$000)

	2020 Q2E	2020 Q2A	Better/(worse) than forecast
<b>Income Statement</b>			
Total Revenue	\$25,000	\$24,040	(\$960)
Total cost of revenue	10,000	8,345	1,655
Total Gross Profit	15,000	15,696	696
Operating expenses:			
Selling and marketing	300	390	(90)
Administrative and general	1,600	2,191	(591)
R&D	420	750	(330)
Depreciation and amortization	20	25	(5)
Total Expenses	2,340	3,357	(1,017)
Earnings (loss) from Operations	12,660	12,339	(321)
Total Other income/(expense)	0	297	297
Earnings before taxes	12,660	12,636	(24)
Tax expense/(benefit)	0	0	0
Net income	<u>12,660</u>	<u>\$12,636</u>	<u>(\$24)</u>
EPS	\$ 0.46	\$ 0.43	\$ (0.03)
Diluted common shares	27,457	29,152	
<b>Income Statement</b>			
Total Revenue	100%	100%	
Total cost of revenue	40%	35%	
Total Gross Profit	60.0%	65.3%	53 bps

Source: Company filings and Litchfield Hills Research LLC

Figure 6 – Co-Diagnostics, Inc. – Comp Table

Identifier (RIC)	Company Name	8/14 Close	Market Cap \$MM	EV \$MM	2020 PE	2021 PE	2020 Sales Multiple	2021 Sales Multiple	2020 EV / EBITDA	2021 EV / EBITDA	2020 EV / Revenue	2021 EV / Revenue
RHHBY.PK	Roche Holding AG	\$42.55	294,880		16.18	15.20	4.46	4.28				
ABT.N	Abbott Laboratories	\$99.99	177,035	191,897	30.79	25.47	5.41	4.90	23.21	19.62	5.85	5.30
TMO	Thermo Fisher Scientific I	\$413.76	163,679	179,174	27.43	24.87	5.83	5.42	23.06	21.03	6.38	5.92
DHR	Danaher Corp	\$204.86	145,329	165,456	37.25	31.96	6.82	6.01	28.69	24.35	7.75	6.83
SIEGY.PK	Siemens AG	\$68.40	116,687	149,883	20.21	16.18	1.36	1.29	16.08	13.93	2.22	2.04
ILMN.O	Illumina Inc	\$347.56	50,744	48,638	NA	NA	16.48	12.91	NA	35.78	15.83	12.37
BIOX.PA	Biomerieux SA	\$163.41	19,293	19,777	48.50	44.21	5.55	5.28	24.65	22.94	5.44	5.14
HOLX.O	Hologic Inc	\$66.81	17,303	19,879	22.44	16.04	5.05	4.10	16.30	12.26	5.81	4.69
QGEN.N	Qiagen NV	\$49.45	11,414	12,376	24.68	20.72	6.42	5.78	16.73	14.17	6.79	5.95
GH.O	Guardant Health Inc	\$85.46	8,497	7,609			30.45	22.78			NA	NA
096530.KQ	Seegene Inc	\$186.53	4,893	4,806	14.91	17.02	7.85	9.19	10.30	12.73	6.68	7.31
LMNX.O	Luminex Corp	\$30.87	1,431	1,338	36.47	43.07	3.40	3.20	16.27	17.82	3.17	3.01
GNMK.O	Genmark Diagnostics Inc	\$15.23	1,082	1,020			6.62	6.38		NA	6.25	6.01
FLGT.O	Fulgent Genetics Inc	\$42.02	918	897	37.76	22.75	7.26	5.14	23.81	18.33	7.09	5.01
AXDX.O	Accelerate Diagnostics Ir	\$14.51	818	869			66.80	31.54			NA	NA
TTOO.O	T2 Biosystems Inc	\$1.48	219	227			11.58	6.30			11.88	5.87
BNGO.O	Bionano Genomics Inc	\$0.70	98	106			13.99	5.97			15.34	6.56
ATOS.O	Atossa Therapeutics Inc	\$3.71	39	32				11.10				9.14
IDXG.OQ	Interpace Biosciences Inc	\$5.78	23	58			0.69	0.48			1.70	1.19
<b>AVERAGE</b>					<b>28.78</b>	<b>25.23</b>	<b>11.45</b>	<b>8.00</b>	<b>19.91</b>	<b>19.36</b>	<b>7.21</b>	<b>5.77</b>
CODX.O	Co-Diagnostics Inc	\$16.29	457	439	8.97	7.85	4.95	4.03	11.70	13.06	4.96	4.10
<b>CODX Discount to Peers</b>					<b>69%</b>	<b>69%</b>	<b>57%</b>	<b>50%</b>	<b>41%</b>	<b>33%</b>	<b>31%</b>	<b>29%</b>

Certain comparable metrics were excluded with NA because they would have made the comparison even worse had we used them.

Source: Litchfield Hills Research LLC and Refinitiv Eikon (formerly Thomson Reuters Eikon)

*Figure 7 – Co-Diagnostics, Inc. – Income Statement (\$000)*

November ending year	2017	2018	2019A				2019A	2020E				2020E	2021E				2021E
	Year	Year	Q1A	Q2A	Q3A	Q4A	Year	Q1A	Q2A	Q3E	Q4E	Year	Q1E	Q2E	Q3E	Q4E	Year
<b>Total revenue</b>	\$8	\$40	\$3	\$62	\$41	\$109	\$215	\$1,549	\$24,040	\$30,000	\$35,000	\$90,589	\$40,000	\$45,000	\$50,000	\$50,000	\$185,000
Cost of Goods	0	9	0	39	20	53	112	482	8,345	12,000	14,000	34,826	18,000	20,250	22,500	22,500	83,250
<b>Gross Profit</b>	7	31	3	23	21	56	103	1,067	15,696	18,000	21,000	55,762	22,000	24,750	27,500	27,500	101,750
Selling and marketing	427	1,166	256	252	262	291	1,062	268	390	400	400	1,459	425	450	475	500	1,850
Administrative and general	3,096	3,571	640	808	1,061	988	3,497	1,459	2,191	2,300	3,000	8,951	3,000	3,000	3,200	3,300	12,500
R&D	1,003	1,361	347	313	331	381	1,371	400	750	800	1,000	2,950	1,000	1,000	1,000	1,000	4,000
Depreciation and amortization	46	51	14	16	17	19	66	21	25	30	30	106	25	25	25	25	100
<b>Total Operating Expenses</b>	4,571	6,148	1,257	1,389	1,671	1,679	5,996	2,149	3,357	3,530	4,430	13,465	4,450	4,475	4,700	4,825	18,450
<b>Operating Income</b>	(4,564)	(6,118)	(1,254)	(1,366)	(1,650)	(1,623)	(5,894)	(1,082)	12,339	14,470	16,570	42,297	17,550	20,275	22,800	22,675	83,300
NMF	NMF	NMF	NMF	NMF	NMF	NMF	NMF	NMF	51%	48%	47%	47%	44%	45%	46%	45%	45%
Total Other Items	(2,395)	(154)	(114)	21	(98)	(112)	(302)	17	297	0	0	313	0	0	0	0	0
<b>Pre-Tax Income</b>	(6,959)	(6,272)	(1,368)	(1,344)	(1,748)	(1,735)	(6,196)	(1,065)	12,636	14,470	16,570	42,610	17,550	20,275	22,800	22,675	83,300
Taxes (benefit)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Tax Rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
<b>Net Income (loss)</b>	<b>(\$6,959)</b>	<b>(\$6,272)</b>	<b>(\$1,368)</b>	<b>(\$1,344)</b>	<b>(\$1,748)</b>	<b>(\$1,735)</b>	<b>(\$6,196)</b>	<b>(\$1,065)</b>	<b>\$12,636</b>	<b>\$14,470</b>	<b>\$16,570</b>	<b>\$42,610</b>	<b>\$17,550</b>	<b>\$20,275</b>	<b>\$22,800</b>	<b>\$22,675</b>	<b>\$83,300</b>
<b>EPS, as reported</b>	<b>(\$0.63)</b>	<b>(\$0.50)</b>	<b>(\$0.09)</b>	<b>(\$0.08)</b>	<b>(\$0.10)</b>	<b>(\$0.10)</b>	<b>(\$0.37)</b>	<b>(\$0.05)</b>	<b>\$0.43</b>	<b>\$0.49</b>	<b>\$0.56</b>	<b>\$1.54</b>	<b>\$0.60</b>	<b>\$0.69</b>	<b>\$0.77</b>	<b>\$0.76</b>	<b>\$2.81</b>
Diluted Shares Outstanding	10,960	12,485	16,067	17,018	17,329	17,350	16,757	22,820	29,152	29,252	29,352	27,644	29,452	29,552	29,652	29,752	29,602

Source: Company reports and Litchfield Hills Research LLC

Figure 8 – Co-Diagnostics, Inc. – Balance Sheet (\$000)

November ending year	FY2021E	FY2020E	FY2019A	FY2018	FY2017
<b>Balance sheet</b>					
Current Assets					
Cash and S.T.I.	\$115,943	\$42,143	\$893	\$950	\$3,534
Accounts receivable	20,000	10,000	131	13	0
Inventories	20,000	15,000	197	18	9
Other assets	1,000	1,000	363	70	908
<b>Total Current Assets</b>	<b>156,943</b>	<b>68,143</b>	<b>1,584</b>	<b>1,052</b>	<b>4,452</b>
Net PP&E	2,000	1,000	197	156	166
Other non-current assets	2,000	2,000	434	345	45
<b>Total Assets</b>	<b>\$160,943</b>	<b>\$71,143</b>	<b>\$2,215</b>	<b>\$1,553</b>	<b>\$4,662</b>
Current Liabilities					
Accounts payable	\$6,000	\$2,000	\$6	\$149	\$41
Accrued expenses	5,000	4,000	321	294	577
Other current liabilities	1,000	500	1	1,909	11
<b>Total current liabilities</b>	<b>12,000</b>	<b>6,500</b>	<b>328</b>	<b>2,352</b>	<b>628</b>
Conv. and Long Term Debt	0	0	0	0	0
Other non-current	0	0	150	260	184
<b>Total Liabilities</b>	<b>12,000</b>	<b>6,500</b>	<b>478</b>	<b>2,612</b>	<b>812</b>
Stockholders' Equity					
Preferred stock	0	0	0	0	0
Common stock	0	0	17	13	12
Additional paid-in-capital	48,000	47,000	26,688	17,622	16,261
Retained earnings	100,943	17,643	(24,968)	(18,694)	(12,422)
Cum. trans. adj. and treasury stock	0	0	0	0	0
<b>Total stockholders' equity</b>	<b>148,943</b>	<b>64,643</b>	<b>1,737</b>	<b>(1,059)</b>	<b>3,851</b>
<b>Total Liabilities and equity</b>	<b>\$160,943</b>	<b>\$71,143</b>	<b>\$2,215</b>	<b>\$1,553</b>	<b>\$4,662</b>

Source: Company reports and Litchfield Hills Research LLC

Figure 9 – Co-Diagnostics, Inc. – Cash Flow (\$000)

	2021E	2020E	2019A	2018	2017
Net Income	\$83,300	\$42,610	(\$6,196)	(\$6,272)	(\$6,959)
Accounts receivable	(10,000)	(9,869)	(118)	(13)	0
Inventories	(5,000)	(14,803)	(179)	(9)	(9)
Other assets	0	(637)	(292)	838	(908)
PP&E	(1,000)	(803)	(41)	9	(166)
Other non-current	0	(1,566)	(89)	(300)	(45)
Accounts payable	4,000	1,994	(143)	108	40
Accrued expenses	1,000	3,679	26	(282)	574
Other current liabilities	500	499	(1,907)	1,898	11
Conv. and Long Term Debt	0	0	0	0	(0)
Other non-current	0	(150)	(110)	76	184
Preferred stock	0	0	0	0	0
Common stock	0	(17)	4	1	12
Additional paid-in-capital	1,000	20,312	9,065	1,362	16,254
Stock subscription receivable	0	0	0	0	0
Other			(78)	0	0
Total Cash Flow	\$73,800	\$41,250	(\$57.10)	(\$2,584)	\$8,988

Source: Litchfield Hills Research LLC

#### Disclosures:

##### Analyst Certification

We, the Litchfield Hills Research Department, hereby certify that the views expressed in this research report accurately reflect our personal views about the subject company and the underlying securities.

##### FINRA Compliant Research Report

We, the Litchfield Hills Research Department, hereby certify that this report is compliant with FINRA research rules 2241, 3110, the analyst is registered with FINRA and the report has been reviewed by a Supervisory Analyst.

##### MiFID II Compliant Research Report

Our research is classified as minor non-monetary benefit under MiFID II. This applies to all forms of transmission, including email, website and financial platforms such as Bloomberg, FactSet, S&P Global, Refinitiv and 13 others. We do not seek payment from the asset management community and do not have any execution function. Investors can continue to receive our research under the MiFID II regime without the need for a contract for services to be put in place. This applies to all forms of transmission, including email, website and financial platforms.

##### Litchfield Hills Research LLC Rating System

**BUY:** We expect the stock to provide a total return of 15% or more within a 12-month period.

**HOLD:** We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

**SELL:** We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

##### Other Disclosures

Litchfield Hills Research, LLC ("LHR") is not a U.S. broker-dealer registered with the U.S. Securities and Exchange Commission nor a member of Financial Industry Regulatory Authority. The principal of LHR and publisher of this report, Theodore R. O'Neill, is a registered representative of Ascendant Capital Markets, LLC ("Ascendant"), a registered broker-dealer and FINRA member firm. Ascendant considers Mr. O'Neill's association with LHR to be an "outside business activity" and is disclosed as such with FINRA. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject LHR or any divisions, subsidiaries or affiliates to any registration or licensing requirement within such jurisdiction.



All material presented in this report, unless specifically indicated otherwise, is under copyright to LHR and the subject company. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of LHR or the subject company. All trademarks, service marks and logos used in this report are trademarks, service marks, registered trademarks, or service marks of LHR or its affiliates. The information, tools and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. LHR may not have taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments or investment services. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable, appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you. LHR does not offer advice on the tax consequences of investment and you are advised to contact an independent tax adviser. LHR believes the information and opinions in the Disclosure Appendix of this report are accurate and complete. Information and opinions presented in this report were obtained or derived from sources LHR believes are reliable, but LHR makes no representations as to their accuracy or completeness.

**Ownership and Material Conflicts of Interest**

The analyst owns no shares of the subject company. The analyst and his family have no known material conflicts of interest in authoring this report. No employees of Ascendant Capital Markets, LLC own any material amount of CODX stock or have any influence on the CODX Board of Directors.

**Investment Banking and Fees for Services**

Litchfield Hills Research has not received compensation for advisory or investment banking services from the Company in the past 12 months. Ascendant Capital Markets, LLC has not received compensation for advisory or investment banking services from the Company in the past 12 months. Litchfield Hills Research LLC has received compensation for distribution and investor targeting services. Ascendant Capital Markets, LLC has not received compensation for non-investment banking services from the Company in the past 12 months.

**Market Making**

Neither Litchfield Hills Research, LLC nor Ascendant Capital Markets, LLC makes a market in the subject company's securities.

Additional information is available upon request. LHR accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that liability arises under specific statutes or regulations applicable to LHR. This report is not to be relied upon in substitution for the exercise of independent judgment.